Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 79-83

  Tao, Yong ^a,b   Libondi, Teodosio ^a,c   Jonas, Jost B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BEVACIZUMAB; NEOMYCIN; POLYMYXIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DRUG EFFECT; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; FOVEAL THICKNESS; HUMAN; INTRAOCULAR PRESSURE; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PARAMETER; REFRACTOMETRY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID; TONOMETRY; TRAUMATIC CATARACT; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77649287199     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0095     Document Type: Article

References (29)

1. Rosenfeld, P.J., Moshfeghi, A.A., and Puliafi to, C.A. Optical coherence tomography fi ndings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging. 36:331-335, 2005.
2. Bashshur, Z.F., Bazarbachi, A., Schakal, A., et al. Intravitreal bevacizumab for the management of choroidal neovascular-ization in age-related macular degeneration. Am. J. Ophthalmol. 142:1-9, 2006.
3. Algvere, P.V., Steen, B., Seregard, S., et al. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 86:482-489, 2008.
4. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bev-acizumab (Avastin) for neovascular age-related macular degen-eration. Ophthalmology. 113:363-372, e365, 2006.
5. Azad, R.V., Khan, M.A., Chanana, B., et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn. J. Ophthalmol. 52:52-56, 2008.
6. Bashshur, Z.F., Haddad, Z.A., Schakal, A., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 145:249-256, 2008.
7. Cleary, C.A., Jungkim, S., Ravikumar, K., et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6-and 9-month results. Eye. 22:82-86, 2008.
8. Emerson, M.V., Lauer, A.K., Flaxel, C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 27:439-444, 2007.
9. Fong, K.C., Kirkpatrick, N., Mohamed, Q., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular de-generation using a variable frequency regimen in eyes with no previous treatment. Clin. Exp. Ophthalmol. 36:748-755, 2008.
10. Goff, M.J., Johnson, R.N., McDonald, H.R., et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular generation. Retina. 27:432-438, 2007.
11. Pedersen, R., Soliman, W., Lund-Andersen, H., et al. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol. Scand. 85:526-533, 2007.
12. Goverdhan, S.V., and Lochhead, J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neo-vascularisation in age-related macular degeneration. Br. J. Ophthalmol. 92:210-212, 2008.
13. Jonas, J.B., Ihloff, A.K., Harder, B., et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic. Res. 41:21-27, 2009.
14. Melamud, A., Stinnett, S., and Fekrat, S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: effi cacy of three consecutive monthly injections. Am. J. Ophthalmol. 146:91-95, 2008.
15. Stifter, E., Michels, S., Prager, F., et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am. J. Ophthalmol. 144:886-892, 2007.
16. Theodossiadis, P.G., Grigoropoulos, V.G., Emfi etzoglou, I., et al. Intravitreal bevacizumab for the treatment of feeder vessel of subfoveal choroidal neovascularization. Eur. J. Ophthalmol. 17:853-856, 2007.
17. Chen, C.Y., Wong, T.Y., and Heriot, W.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am. J. Ophthalmol. 143:510-512, 2007.
18. Arias, L., Caminal, J.M., Casas, L., et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br. J. Ophthalmol. 92:1636-1641, 2008.
19. Bashshur, Z.F., Haddad, Z.A., Schakal, A.R., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am. J. Ophthalmol. 148:59-65, 2009.
20. Forooghian, F., Cukras, C., Meyerle, C.B., et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 29:723-731, 2009.
21. Shah, A.R., and Del Priore, L.V. Duration of action of Intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br. J. Ophthalmol. 93:1027-1032, 2009.
22. Holladay, J.T. Visual acuity measurements. J. Cataract Refract. Surg. 30:287-290, 2004.
23. Brown, D.M., Michels, M., Kaiser, P.K., et al. Ranibizumab versus verteporfi n photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 116:57-65, 2009.
24. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006.
25. Ip, M.S., Scott, I.U., Brown, G.C., et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 115:1837-1846, 2008.
26. Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfi n for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1432-1444, 2006.
27. Jonas, J.B., Libondi, T., Ihloff, A.K., et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol. 85:563-565, 2007.
28. Panda-Jonas, S., Jonas, J.B., and Jakobczyk-Zmija, M. Retinal photoreceptor density decreases with age. Ophthalmology. 102:1853-1859, 1995.
29. Panda-Jonas, S., Jonas, J.B., and Jakobczyk-Zmija, M. Retinal pigment epithelium cell count, density and correlations in normal human eyes. Am. J. Ophthalmol. 121:181-189, 1996.